In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics

The 185 kDa transmembrane glycoprotein human epidermal growth factor receptor 2 (HER-2) (p185/neu, c-ErbB-2) is overexpressed in breast and ovarian cancers. Overexpression in breast cancer correlates with poor patient prognosis, and visualization of HER-2 expression might provide valuable diagnostic information influencing patient management. We have previously described the generation of a new type of affinity ligand, a 58-amino-acid affibody (Z(HER2:4)) with specific binding to HER-2. In order to benefit from avidity effects, we have created a bivalent form of the affibody ligand, (Z(HER2:4))(2). The monovalent and bivalent ligands were compared in various assays. The new bivalent affibody has a molecular weight of 15.6 kDa and an apparent affinity (K-D) against HER-2 of 3 W After radioiodination, using the linker molecule N-succinimidyl p-(trimethylstannyl) benzoate (SPMB), in vitro binding assays showed specific binding to HER-2 overexpressing cells. Internalization of I-125 was shown after delivery with both the monovalent and the bivalent affibody. The cellular retention of I-125 was longer after delivery with the bivalent affibody when,compared to delivery with the monovalent affibody. With approximately the same affinity as the monoclonal antibody trastuzumab (Herceptin (TM)) but only one tenth of the size, this new bivalent molecule is a promising candidate for radionuclide-based detection of HER-2 expression in tumors. I-125 was used in this study as a surrogate marker for the diagnostically relevant radioisotopes I-123 for single photon emission computed tomography (SPECT)/gamma-camera imaging and I-124 for positron emission tomography (PET).